egnite 2026 Benchmark Report

egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none.

ALISO VIEJO, Calif., Oct. 21, 2026 — egnite, Inc., a technology company advancing guideline-directed cardiovascular care and real-world evidence, today released its 2026 Benchmark Report on Heart Failure and Structural Heart, which examines how cardiovascular care is delivered across 47 U.S. health systems. It updates the 2023 report and draws on de-identified data from the egnite Registry of more than 15.7 million patients and 6 million echo reports, across 830 facilities in the company’s network.

egnite‘s data shows that prescribing of all four guideline-directed medical therapy (GDMT) classes for systolic heart failure rose from 9% to 21% since the 2023 report, and prescribing of three or more classes rose from 31% to 46%. The growth is consistent with rapid adoption of SGLT2 inhibitors.

New analysis of more than 650,000 real-world systolic heart failure patients featured in the report reveals a strong association between three-year survival and the number of GDMT classes prescribed. Three-year survival was 76% among patients prescribed four classes, compared with 52% among patients prescribed none, a difference of 24 percentage points.

Read the Full Release